首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2018年 2期丙型肝炎的治疗 => 综述 =>丙型肝炎直接抗病毒药物治疗与肝癌..
丙型肝炎直接抗病毒药物治疗与肝癌发生及复发的关系
Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer
文章发布日期:2018年01月05日  来源:  作者:李砚,刘蕾,罗书兰,等  点击次数:615次  下载次数:104次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:HCV感染后引起的慢性肝炎,是导致肝硬化和肝细胞癌的主要原因之一。近年来,直接抗病毒药物 (DAA)逐渐成为治疗丙型肝炎的主流药物。研究表明DAA可能会增加HCV相关肝硬化患者发生肝癌或者导致肝癌复发的风险,给DAA的临床应用带来了巨大的争议。综述了DAA对肝癌发生和复发的影响,以期为DAA的临床应用提供更好的依据。
【Abstract】:Chronic hepatitis caused by hepatitis C virus (HCV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma. In recent years, direct-acting antiviral agents (DAAs) have gradually become main drugs for the treatment of hepatitis C. Studies have shown that DAAs may increase the risk of the development or recurrence of liver cancer in patients with HCV-related liver cirrhosis, which causes great controversies over the clinical application of DAAs. This article reviews the influence of DAAs on the development and recurrence of liver cancer, in order to provide a better basis for the clinical application of DAAs.
【关键字】:hepatitis C; carcinoma, hepatocellular; antiviral agents; review
【Key words】:
【引证本文】:LI Y, LIU L, LUO SL, et al. Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer[J]. J Clin Hepatol, 2018, 34(2): 410-413. (in Chinese)
李砚, 刘蕾, 罗书兰, 等. 丙型肝炎直接抗病毒治疗与肝癌发生及复发的关系[J]. 临床肝胆病杂志, 2018, 34(2): 410-413.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号